South Korea-based medical AI company VUNO has achieved a significant milestone by securing a Japanese patent for its AI-powered cardiac arrest risk monitoring system, VUNO Med-DeepCARS (DeepCARS). This innovative technology leverages artificial intelligence to enhance prediction accuracy, even in environments with limited input variables.
Breakthrough AI Technology for Consistent Predictions
The patented method employs a graph neural network (GNN) model to analyze relationships between available patient data. Unlike traditional approaches that require extensive and specific data sets, VUNO’s technology adapts seamlessly to varied clinical environments.
In real-world scenarios, patient data can vary widely:
ICU settings often provide detailed metrics, such as blood test results.
General wards typically collect fewer data points due to less invasive monitoring techniques.
Despite these challenges, DeepCARS can generate reliable predictions using a combination of vital signs (e.g., blood pressure and pulse) and available blood test data. By removing the need for custom models tailored to individual hospitals, this technology simplifies implementation across diverse healthcare facilities.
Advancing Global Market Expansion
“This patent registration marks an essential step in introducing DeepCARS to the Japanese market,” said Lee Ye-ha, CEO of VUNO. “The technology is also under review for FDA approval in the U.S. as part of our efforts to expand globally.”
VUNO Med-DeepCARS demonstrates how cutting-edge AI can address clinical challenges, empowering healthcare providers with tools to make life-saving predictions more effectively and consistently.
